

Luca Vago

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9215033/publications.pdf>

Version: 2024-02-01

67
papers

4,535
citations

126858

33
h-index

106281

65
g-index

69
all docs

69
docs citations

69
times ranked

5278
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 361, 478-488.	13.9	459
2	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , 2009, 10, 489-500.	5.1	458
3	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	15.2	253
4	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
5	KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. <i>Journal of Experimental Medicine</i> , 2009, 206, 2557-2572.	4.2	211
6	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	0.6	164
7	Immune escape and immunotherapy of acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2020, 130, 1552-1564.	3.9	160
8	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 114, 1437-1444.	0.6	131
9	Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. <i>Experimental Hematology</i> , 2009, 37, 616-628.e2.	0.2	121
10	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1506-1514.	2.0	121
11	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	5.8	120
12	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. <i>Blood</i> , 2015, 125, 2865-2874.	0.6	119
13	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. <i>Leukemia</i> , 2015, 29, 396-405.	3.3	114
14	Temporal, quantitative, and functional characteristics of single-KIR ⁺ positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3488-3499.	0.6	113
15	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. <i>Leukemia</i> , 2015, 29, 1143-1152.	3.3	110
16	Improving the safety of cell therapy with the TK-suicide gene. <i>Frontiers in Pharmacology</i> , 2015, 6, 95.	1.6	102
17	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. <i>Science Translational Medicine</i> , 2015, 7, 317ra198.	5.8	102
18	Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2019, 133, 1290-1297.	0.6	100

#	ARTICLE	IF	CITATIONS
19	The Impact of Amino Acid Variability on Alloreactivity Defines a Functional Distance Predictive of Permissive HLA-DPB1 Mismatches in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 233-241.	2.0	95
20	Epidemiology and biology of relapse after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1379-1389.	1.3	85
21	Mutation at Positively Selected Positions in the Binding Site for HLA-C Shows That KIR2DL1 Is a More Refined but Less Adaptable NK Cell Receptor Than KIR2DL3. <i>Journal of Immunology</i> , 2012, 189, 1418-1430.	0.4	76
22	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. <i>Blood</i> , 2017, 130, 606-618.	0.6	71
23	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	0.6	66
24	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. <i>Frontiers in Immunology</i> , 2017, 8, 1444.	2.2	62
25	Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. <i>Immunity</i> , 2021, 54, 737-752.e10.	6.6	58
26	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, e157-e161.	1.7	55
27	Genomic Loss of Mismatched Human Leukocyte Antigen and Leukemia Immune Escape From Haploidentical Graft-Versus-Leukemia. <i>Seminars in Oncology</i> , 2012, 39, 707-715.	0.8	51
28	Frequency and Targeted Detection of HLA-DPB1 T Cell Epitope Disparities Relevant in Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1031-1040.	2.0	50
29	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 120, 1820-1830.	0.6	47
30	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	2.8	43
31	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. <i>Blood</i> , 2021, 138, 2655-2669.	0.6	43
32	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. <i>Blood</i> , 2012, 119, 4813-4815.	0.6	42
33	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 147.	2.2	39
34	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2250-2255.	2.0	36
35	High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 629-636.	1.1	35
36	Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 207.	1.8	32

#	ARTICLE	IF	CITATIONS
37	A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT. <i>Blood</i> , 2017, 130, 1270-1273.	0.6	31
38	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2012, 19, 427-433.	1.2	30
39	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	0.6	26
40	Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse. <i>Cancer Discovery</i> , 2022, 12, 1449-1461.	7.7	26
41	Significantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities. <i>Blood</i> , 2010, 116, 1991-1992.	0.6	24
42	Expertsâ€™ considerations on HLA-haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 187-197.	1.1	24
43	CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. <i>Science Translational Medicine</i> , 2022, 14, eabg8027.	5.8	21
44	Choosing the Alternative. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1813-1814.	2.0	18
45	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. <i>Leukemia</i> , 2021, 35, 585-594.	3.3	18
46	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	1.3	18
47	Clonal evolution and immune evasion in posttransplantation relapses. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 610-616.	0.9	15
48	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	2.0	14
49	Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. <i>Leukemia</i> , 2008, 22, 2119-2122.	3.3	12
50	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-versus-host disease prediction after unrelated donor hematopoietic cell transplantation. <i>Haematologica</i> , 2020, 105, e186-e189.	1.7	12
51	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. <i>Bone Marrow Transplantation</i> , 2015, 50, 1262-1264.	1.3	11
52	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. <i>Bone Marrow Transplantation</i> , 2018, 53, 1201-1205.	1.3	10
53	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 410-416.	1.3	10
54	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2016, 51, 1022-1024.	1.3	6
56	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. <i>Bone Marrow Transplantation</i> , 2016, 51, 466-469.	1.3	6
57	Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study. <i>Haematologica</i> , 2021, 106, 1480-1483.	1.7	5
58	Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 115.	6.9	4
59	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	0.6	4
60	Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 678-680.	1.3	4
61	Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210908.	1.1	3
62	Elderly patients >65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. <i>American Journal of Hematology</i> , 2016, 91, E302-3.	2.0	2
63	Nanosphere's Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. <i>Clinical Hematology International</i> , 2019, 1, 120-123.	0.7	2
64	Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 206.e1-206.e6.	0.6	2
65	Therapy-Induced Senescence As an Anti-Cancer and Immune-Stimulatory Strategy. <i>Blood</i> , 2021, 138, 4419-4419.	0.6	1
66	Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type. <i>Current Research in Translational Medicine</i> , 2021, 69, 103313.	1.2	0
67	Mechanisms of Immune Resistance. , 2019, , 457-460.		0